<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641301</url>
  </required_header>
  <id_info>
    <org_study_id>OBEMO2</org_study_id>
    <nct_id>NCT02641301</nct_id>
  </id_info>
  <brief_title>Sustained-release Morphine Pharmacokinetics in Roux-en-Y Gastric Bypass Subjects</brief_title>
  <acronym>OBEMO2</acronym>
  <official_title>Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Lariboisière</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sustained release morphine pharmacokinetics
      parameters in patients undergone roux-en-y gastric bypass (RYGB) differ from subjects who did
      not. Our hypothesis is that exposure is comparable. Indeed, in the Study OBEMO (Determinants
      of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass; NCT00943969)
      the investigators observed changes in pharmacokinetics parameters for immediate release
      morphine, probably due to an earlier absorption of the morphine, in agreement with the
      expected clinical effect of this formulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label study with two arms: patients undergone roux-en-y gastric bypass and
      volunteers who did not matched by sex, age and Body Mass Index (BMI). In the pharmacokinetic
      visit the subject takes an oral administration of sustained release morphine, 30 mg, then 11
      samples are collected during 12 hours.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine area under the curve (AUC0-inf) after its oral administration according to the morphine concentration.</measure>
    <time_frame>During the study visit: morphine concentration at time hour 0,5 ; hour 1; hour 1,5 ; hour 2; hour2,5; hour3; hour 4; hour 5; hour 6; hour 8; hour 12 after its oral administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under ther curve [AUC] of morphine-3-glucuronide, morphine-6-glucuronide</measure>
    <time_frame>During the study visit: concentration at time hour 0,5 ; hour 1; hour 1,5 ; hour 2; hour2,5; hour3; hour 4; hour 5; hour 6; hour 8; hour 12 after morphine oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum plasma concentration [Tmax] of morphine, morphine-3-glucuronide, morphine-6-glucuronide</measure>
    <time_frame>During the study visit: concentrations at time hour 0,5 ; hour 1; hour 1,5 ; hour 2; hour2,5; hour3; hour 4; hour 5; hour 6; hour 8; hour 12 after morphine oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed clearance [Cl/F] of morphine, morphine-3-glucuronide, morphine-6-glucuronide</measure>
    <time_frame>During the study visit: concentrations at time 0,5h; 1h; 1,5h; 2h; 2,5h; 3h; 4h; 5h; 6h; 8h; 12h after morphine oral administration</time_frame>
    <description>Blood samples gathered from hour 0,5 to hour 12 and urine sample gathered from the start to the end of the study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Volume of distribution [Vd / F] of morphine, morphine-3-glucuronide, morphine-6-glucuronide</measure>
    <time_frame>During the study visit: concentrations at time hour 0,5 ; hour 1; hour 1,5 ; hour 2; hour2,5; hour3; hour 4; hour 5; hour 6; hour 8; hour 12 after morphine oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Half-Life [T1 /2] of morphine, morphine-3-glucuronide, morphine-6-glucuronide</measure>
    <time_frame>During the study visit: concentrations at time hour 0,5 ; hour 1; hour 1,5 ; hour 2; hour2,5; hour3; hour 4; hour 5; hour 6; hour 8; hour 12 after morphine oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration [Cmax] of morphine, morphine-3-glucuronide, morphine-6-glucuronide</measure>
    <time_frame>During the study visit: concentrations at time hour 0,5 ; hour 1; hour 1,5 ; hour 2; hour2,5; hour3; hour 4; hour 5; hour 6; hour 8; hour 12 after morphine oral administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bypass Complications</condition>
  <arm_group>
    <arm_group_label>Subjects Roux-en-Y-gastric bypass (RYGB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sustained release morphine sulfate, 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control volunteers matched with RYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sustained release morphine sulfate, 30 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained release morphine sulfate, 30 mg</intervention_name>
    <description>A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.</description>
    <arm_group_label>Subjects Roux-en-Y-gastric bypass (RYGB)</arm_group_label>
    <arm_group_label>Control volunteers matched with RYGB</arm_group_label>
    <other_name>Code : 333 236-9 ; Access market authorisation 3400933323691</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        RYGB Group (n=12) :

          -  Subjects who undergone RYGB for at least 24 months

          -  Stable weight since almost one year (or weight loss below 10kg over the last year)

        Control group (n=12) :

          -  Volunteers subjects, matched for age, sex, and Body mass index

          -  No history of bariatric surgery

        Same characteristics

          -  Subjects volunteers for the study

          -  Age 20-65 years

          -  Written consent

        Exclusion Criteria:

          -  Known allergy to morphine or naloxone

          -  Patients not affiliated to the french social security system

          -  Subjects yet recruited in a study with remuneration

          -  Abnormalities in liver function Prothrombin ratio &lt;70% and/ or aspartate transaminase
             &gt; 5 times the usual values and/ or alanine aminotransferase &gt;5 times the usual values
             and/ or in renal function (creatinine clearance Modification of Diet in Renal Disease
             (MDRD) &lt; 60ml/ min

          -  Respiratory insufficiency defined by an oximetry below 90%

          -  Pregnancy and breastfeeding

          -  Use of drugs contra-indicated or not advised with morphine:

          -  Agonists-antagonists opioids ( buprenorphine, nalbuphine, pentazocine ), naltrexone

          -  Alcohol intake &gt; 30g by day

          -  Cough medicine morphine-like ( dextromethorphan, noscapine, pholcodine )

          -  Codeine, ethylmorphine

          -  Other morphine agonist ( alfentanil, codeine, dextromoramide, dextropropoxyphene,
             dihydrocodeine, fentanyl, oxycodone, pethidin, phenoperidine, remifentanil,
             sufentanil, tramadol )

          -  Barbiturates, benzodiazepines

          -  Rifampicin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois JB Bergmann, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Lariboisiere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Therapeutic Research Unit, Department of Internal Medicine, Hospital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011 Feb 12;377(9765):557-67. doi: 10.1016/S0140-6736(10)62037-5. Epub 2011 Feb 3.</citation>
    <PMID>21295846</PMID>
  </reference>
  <reference>
    <citation>Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004 Dec 23;351(26):2683-93.</citation>
    <PMID>15616203</PMID>
  </reference>
  <reference>
    <citation>Padwal RS, Gabr RQ, Sharma AM, Langkaas LA, Birch DW, Karmali S, Brocks DR. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011 Jun;34(6):1295-300. doi: 10.2337/dc10-2140. Epub 2011 Apr 8.</citation>
    <PMID>21478461</PMID>
  </reference>
  <reference>
    <citation>Skottheim IB, Stormark K, Christensen H, Jakobsen GS, Hjelmesaeth J, Jenssen T, Reubsaet JL, Sandbu R, Asberg A. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009 Sep;86(3):311-8. doi: 10.1038/clpt.2009.82. Epub 2009 Jun 3.</citation>
    <PMID>19494810</PMID>
  </reference>
  <reference>
    <citation>Hamad GG, Helsel JC, Perel JM, Kozak GM, McShea MC, Hughes C, Confer AL, Sit DK, McCloskey CA, Wisner KL. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012 Mar;169(3):256-63. doi: 10.1176/appi.ajp.2011.11050719.</citation>
    <PMID>22407114</PMID>
  </reference>
  <reference>
    <citation>Raebel MA, Newcomer SR, Reifler LM, Boudreau D, Elliott TE, DeBar L, Ahmed A, Pawloski PA, Fisher D, Donahoo WT, Bayliss EA. Chronic use of opioid medications before and after bariatric surgery. JAMA. 2013 Oct 2;310(13):1369-76. doi: 10.1001/jama.2013.278344.</citation>
    <PMID>24084922</PMID>
  </reference>
  <reference>
    <citation>Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993 Apr;24(4):344-54.</citation>
    <PMID>8491060</PMID>
  </reference>
  <reference>
    <citation>Gourlay GK. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet. 1998 Sep;35(3):173-90. Review.</citation>
    <PMID>9784932</PMID>
  </reference>
  <reference>
    <citation>Lloret-Linares C, Hirt D, Bardin C, Bouillot JL, Oppert JM, Poitou C, Chast F, Mouly S, Scherrmann JM, Bergmann JF, Declèves X. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. Clin Pharmacokinet. 2014 Oct;53(10):919-30. doi: 10.1007/s40262-014-0163-0.</citation>
    <PMID>25141973</PMID>
  </reference>
  <reference>
    <citation>Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013 Apr;23(4):427-36. doi: 10.1007/s11695-012-0864-0.</citation>
    <PMID>23338049</PMID>
  </reference>
  <reference>
    <citation>Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010 Jan;11(1):41-50. doi: 10.1111/j.1467-789X.2009.00614.x. Epub 2009 Jun 2. Review.</citation>
    <PMID>19493300</PMID>
  </reference>
  <reference>
    <citation>Skottheim IB, Jakobsen GS, Stormark K, Christensen H, Hjelmesaeth J, Jenssen T, Asberg A, Sandbu R. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin Pharmacol Ther. 2010 Jun;87(6):699-705. doi: 10.1038/clpt.2010.32. Epub 2010 May 5.</citation>
    <PMID>20445535</PMID>
  </reference>
  <reference>
    <citation>Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301-16. doi: 10.1146/annurev.med.080708.082713. Review.</citation>
    <PMID>19824817</PMID>
  </reference>
  <reference>
    <citation>Lötsch J, Weiss M, Ahne G, Kobal G, Geisslinger G. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Anesthesiology. 1999 Apr;90(4):1026-38.</citation>
    <PMID>10201674</PMID>
  </reference>
  <reference>
    <citation>Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther. 2003 Dec;74(6):543-54.</citation>
    <PMID>14663457</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital Lariboisière</investigator_affiliation>
    <investigator_full_name>Célia Lloret-Linares, MD PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>Roux-en-Y-gastric bypass</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Pain</keyword>
  <keyword>morphine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

